Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.
Fisch MJ, Lee J-W, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30(16):1980–8.
Van den Beuken-van Everdingen M, De Rijke J, Kessels A, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–49.
Shi Q, Smith TG, Michonski JD, et al. Symptom burden in cancer survivors 1 year after diagnosis. Cancer. 2011;117(12):2779–90.
Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353(9165):1695–700.
Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44.
Gomes B, Higginson I, Calanzani N, et al. Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. Ann Oncol. 2012;23(8):2006–15.
Department of Health. End of life care strategy: promoting high quality care for all adults at the end of life. London: DH Publications Orderline; 2008.
Adam R, Wassell P, Murchie P. Why do patients with cancer access out-of-hours primary care? A retrospective study. Br J Gen Pract. 2014;64(619):e99–104.
Faculty of Medicine and Health, University of Leeds. What is the IMPACCT programme? http://medhealth.leeds.ac.uk/info/655/impacct/907/what_is_the_impacct_programme. Accessed 1 Apr 2015.
Campbell NC, Murray E, Darbyshire J, et al. Designing and evaluating complex interventions to improve health care. BMJ. 2007;334(7591):455–9.
Bate P, Robert G. Experience-based design: from redesigning the system around the patient to co-designing services with the patient. Qual Saf Health Care. 2006;15(5):307–10.
de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–72.
Clark MD, Determann D, Petrou S, et al. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883–902.
Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2007.
Molassiotis A, Emsley R, Ashcroft D, et al. Applying best-worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer. 2012;77(1):199–204.
Mühlbacher AC, Junker U, Juhnke C, et al. Chronic pain patients’ treatment preferences: a discrete-choice experiment. Eur J Health Econ. 2015;16(6):613–28.
Chancellor J, Martin M, Liedgens H, et al. Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids. Value Health. 2012;15(1):106–17.
Gregorian RS, Gasik A, Kwong WJ, et al. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11(11):1095–108.
Meghani SH, Chittams J, Hanlon AL, Curry J. Measuring preferences for analgesic treatment for cancer pain: how do African–Americans and Whites perform on choice-based conjoint (CBC) analysis experiments? BMC Med Inform Decis Mak. 2013;13(1):118.
de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373–84.
Coast J, Al-Janabi H, Sutton EJ, et al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21(6):730–41.
Clarke V, Braun V. Thematic analysis. In: Teo T, editor. Encyclopedia of critical psychology. New York: Springer; 2014. p. 1947–52.
Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ. 2005;14(10):1079–83.
Payne K, McAllister M, Davies LM. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22(3):258–71.
Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics. 2013;31(8):677–91.
Loomis J. What’s to know about hypothetical bias in stated preference valuation studies? J Econ Surv. 2011;25(2):363–70.
Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis. Pharmacoeconomics. 2009;27(9):705–12.